Clinical efficacy of programmed cell death 1 monoclonal antibody combined with CHOP regimen in the treatment of malignant lymphoma
Objective To explore the clinical efficacy of programmed cell death 1(PD-1)monoclonal antibody com-bined with cyclophosphamide+epirubicin+vincristine+prednisone(CHOP)regimen in the treatment of malignant lympho-ma(ML).Method A total of 82 ML patients were divided into CHOP group(n=39,CHOP regimen alone)and PD-1 combined treatment group(n=43,PD-1 monoclonal antibody combined with CHOP regimen)according to different treat-ment methods.The clinical efficacy,immune function indexes[CD4+,immunoglobulin G(IgG)and immunoglobulin A(IgA)],inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)],tumor related indexes[vascular en-dothelial growth factor(VEGF),inducible nitric oxide synthase(iNOS),lactate dehydrogenase(LDH)]and the occur-rence of adverse reactions were compared between the two groups.Result The overall response rate of PD-1 combined treatment group was higher than that of CHOP group,and the difference was statistically significant(P<0.05).After treat-ment,the CD4+levels in the two groups were higher than those before treatment,the IgG and IgA levels were lower than those before treatment,and the CD4+level in PD-1 combined treatment group was higher than that in CHOP group,the IgG and IgA levels were lower than those in CHOP group,and the differences were statistically significant(P<0.05).Af-ter treatment,the IL-6,TNF-α,VEGF,iNOS and LDH levels in the two groups were lower than those before treatment,and the IL-6,TNF-α,VEGF,iNOS and LDH levels in PD-1 combined treatment group were lower than those in CHOP group,and the differences were statistically significant(P<0.05).Conclusion PD-1 monoclonal antibody combined with CHOP regimen in the treatment of ML patients can improve clinical efficacy and immune function,reduce inflammatory response and the incidence of adverse reactions.
programmed cell death 1monoclonal antibodyCHOP regimenmalignant lymphomaimmune func-tioninflammatory factor
NETL
NSTL
万方数据
